Urological cancers include Prostate cancer, Bladder cancer, and Kidney
cancer. These cancers have seen major advances in treatment,
particularly through genomic testing, which can identify inherited or
tumour-specific changes in a proportion of patients. In around 7–10% of
cases, a targetable genetic alteration may be found, allowing treatment
to be tailored using specific targeted therapies. In bladder and kidney
cancers, immunotherapy and newer targeted treatments have also
significantly improved outcomes for many patients.

For consultation, Dr De Silva can guide you through the complex world of multidisciplinary cancer care